Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Raw Materials (2021 - 2025)

Veracyte's Raw Materials history spans 5 years, with the latest figure at $20.5 million for Q4 2025.

  • For Q4 2025, Raw Materials rose 14.94% year-over-year to $20.5 million; the TTM value through Dec 2025 reached $20.5 million, up 14.94%, while the annual FY2025 figure was $20.5 million, 14.94% up from the prior year.
  • Raw Materials for Q4 2025 was $20.5 million at Veracyte, up from $20.3 million in the prior quarter.
  • Across five years, Raw Materials topped out at $20.5 million in Q4 2025 and bottomed at $3.0 million in Q4 2021.
  • The 5-year median for Raw Materials is $4.4 million (2022), against an average of $9.6 million.
  • The largest annual shift saw Raw Materials dropped 6.82% in 2023 before it surged 346.9% in 2024.
  • A 5-year view of Raw Materials shows it stood at $3.0 million in 2021, then surged by 36.67% to $4.1 million in 2022, then fell by 2.44% to $4.0 million in 2023, then soared by 346.9% to $17.9 million in 2024, then rose by 14.94% to $20.5 million in 2025.
  • Per Business Quant, the three most recent readings for VCYT's Raw Materials are $20.5 million (Q4 2025), $20.3 million (Q3 2025), and $20.1 million (Q2 2025).